In this study, we selected a cohort of AD patients by not only relying on an accurate clinical and neuropsychological evaluation but also choosing the patients according to the CSF profile of Aβ42, t-tau and p-tau, which further supports the initial AD diagnosis. The gene discussed is MAPT; the disease is Alzheimer disease.